Bioxytran, Inc. · OTC:BIXT
Bioxytran — Investor Presentation (October 2025)
31 slides from Bioxytran's investor presentation, October 2025
Slide 1: Bioxytran Inc. - A Complex Carbohydrate Chemistry Drug Company
Bi XyTran Inc. A Complex Carbohydrate Chemistry Drug Company 1
Slide 2: Forward Looking Statement
Forward Looking Statement This Descriptive Presentation (the “Presentation") has been prepared by Bioxytran, Inc (the “Company”) and recipients are not entitled to rely on the accuracy or completeness of the Presentation. Statistical information contained in this Presentation is based on information
Slide 3: Platform Technologies Addressing 3 Major Problems
Platform Technologies Addressing 3 Major Problems GLYCOVIROLOGY STROKE CANCER METASTASIS PROBLEM ONE PROBLEM TWO PROBLEM THREE Copyright © Bioxytran 2025. All rights. 3
Slide 4: The Problems
The Problems No Effective No Effective Treatment for Viral Treatments for Infections Cancer Metastasis No Treatment for Early-Stage Stroke Copyright © Bioxytran 2025. All rights. 4
Slide 5: Problem Number #1: No Effective Treatment for Viral Infections
PROBLEM NUMBER #1 This is an amount to allow for unexpected issues or services that pop up during the year. Most people allow 5-10%, if the accounts team will let you! No Effective Treatment for Viral Infections
Slide 6: Problem #1: No Effective Treatment for Viral Infections
Problem #1: No Effective Treatment for Viral Infections United States Virology Data COVID-19 Respiratory Syncytial Virus (RSV) 103 million 2.1 million (toddlers) Influenza Viral Conjunctivitis 26 million 5.0 million 2600+ RNA No Broad- Vaccines are Viruses Spectrum solution unable to keep Identified
Slide 7: Galectin Antagonists Block Viral Binding
In 1992 David Platt for the first time identified and named the Galectin 01 Bioxytran develops IP protected Galectin 02 Most viruses need Galectin receptors 03 Galectin Antagonists block the binding Antagonists to bind to cells and neutralize the virus Copyright © Bioxytran 2025. All rights. 7
Slide 8: Key Leadership in Galectin Science
Key Leadership in Galectin Science David Platt PhD, CEO, CSO, Chairman 40+ years of research in Galectins (carbohydrate-binding proteins) Co-author of 2 Textbooks Founder of 5 Public Companies Publication of numerous Journal Articles and Patents Developer of numerous drugs FDA regulatory clinical tr
Slide 9: Broad-Spectrum Antiviral Galectin Antagonists for Humans & Animals
Developing Broad-Spectrum Antiviral Galectin Antagonists for Humans & Animals Complete Viral Clearance shown in 2 Randomized Controlled Clinical trials in a COVID19 Case Study Expansion planned for follow on indications COVID-19 * Influenza RSV * HIV * Conjunctivitis * Shingles * Bird Flu Copyright
Slide 10: Bioxytran's ProLectin-M vs Pfizer's Paxlovid
Bioxytran’s ProLectin-M vs Pfizer’s Paxlovid ◌ Day 3 – 14 out of 17 were PCR negative (88%) ◌ Day 20 PCR negative (30%) ◌ Day 7 – 17 out of 17 were PCR negative (100%) No toxicity signals ◌ Toxicity (Drug to Drug Interactions) ◌ Standard Risk Patients w/o limitations ◌ Limited to Underlying Medical
Slide 11: ProLectin-M - Phase 2 Trial Results
ProLectin-M - Phase 2 Trial Results Press Release Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist 11/16/2022 on COVID-19 Patients in medRxiv Pre-print PR Newswire BOSTON, Nov. 16, 2022 - Complete elimination of viral load in 100% of patients at day 7 vs 6% in p
Slide 12: Possible COVID Resurgence is Brewing
Possible COVID Resurgence is Brewing Existing Solutions are Inadequate Resistance Emerging Rebounds No More virulent COVID Prevention Side Effects Current Antivirals – First variant Spreading in Asia & Last Line of Defense Europe & US ◌ Highly transmissible and ◌ Paxlovid showing immune evasion ◌ Mo
Slide 13: Bioxytran's ProLectin-M
Bioxytran’s ProLectin-M First line of defense for all mutations of coronaviruses⃰ STATUS Clinical Trial Stage. Phase II successfully completed– Phase III Ready under the Central Drugs Standard Control Organization (CDSCO) in India Safety Versatility Efficacy Fast Patient ◌ No Adverse Effects ◌ Mutat
Slide 14: Neutralizing the Spike Protein on Viruses
Neutralizing the Spike Protein on Viruses No Sugar Shield Shielded in Sugar How it Works ANTIBODY Galectin Fold Ideal Binding Site ✓ Binding to the spike protein prevents viral entry ✓ Immensely tighter bond to galectin fold vs tip (ProLectin-RX 99% binding affinity) ✓ Antibodies take time to be pro
Slide 15: Historic Discovery in Virology
Historic Discovery in Virology Similar to the discovery of Antibiotics DISCOVERY Viral adhesion to the cellular membrane is the first step in the process of viral entry and galectins facilitate this process. Both viruses and cells are covered in slippery membranes. Galectins act as the viral glue th
Slide 16: Problem Number #2: No Effective Treatment for Early-Stage Stroke
PROBLEM NUMBER #2 This is an amount to allow for unexpected issues or services that pop up during the year. Most people allow 5-10%, if the accounts team will let you! No Effective Treatment for Early-Stage Stroke
Slide 17: The Brain Stroke Epidemic
The Brain Stroke Epidemic The Golden Hour Dilemma Time to Needle 2.5 hours Equivalent to Onset of Ambulance Arrival and initial Thombolysis or Blockage 9 Years of Aging* symptoms arrives at home assessment and PTCA/CABG Removed treatment in ER A Challenge to Worldwide Healthcare, a $500 Billion Medi
Slide 18: BXT-25 Oxygen Bridge
BXT-25 Oxygen Bridge Erythrocyte Hemoglobin Heme BXT-25 is a hemoglobin-based polymer; 5,000 times smaller than a red blood cell BXT-25 polymer It can be used both in Ischemic and Hemorrhagic Stroke It can penetrate a blood-clot and reach the brain within 3 minutes Reduction of average Time-to-Needl
Slide 19: FDA Approved 510K To Detect Brain Oxygenation
FDA Approved 510K To Detect Brain Oxygenation MDX Viewer solely and exclusively licensed to Bioxytran by MDX Lifesciences Inc. – A clinical end-point for measuring oxygen delivery to the brain in real-time Tissue/brain monitored parameters Mitochondrial NADH (ATP) Brain metabolic score 90 Hb Saturat
Slide 20: Problem #3: No Effective Treatments for Cancer Metastasis
Problem #3 This is an amount to allow for unexpected issues or services that pop up during the year. Most people allow 5-10%, if the accounts team will let you! No Effective Treatments for Cancer Metastasis
Slide 21: Clinical Evidence: Cancer Trial Results - Galectin-3
Clinical Evidence: Cancer Trial Results – Galectin-3 Galectin Antagonist therapy in Cohort 2 had a 100% Objective Response in advanced Melanoma for an 85- day trial using optimal dosage. 1 in 5 had a Complete Response PET Scan Before and After of 50% had Objective Response in Melanoma Melanoma patie
Slide 22: Development Pipeline
Development Pipeline Completed Planned IND Product Indication Preclinical Phase I Phase II Phase III Phase IV Submission Virology – Mild to Moderate ProLectin-M • Covid-19 Oral • Influenza • Other virologic diseases Virology – Severe cases ProLectin-I/C • [I] Covid-19, Long Covid Intravenous • [I] O
Slide 23: IP Strategy
IP Strategy Intellectual Property (IP) Three (3) issued One (1) licensed US Additional worldwide patents patent applications to strengthen our IP position are ongoing Future patents to be filed at commercialization stage Pharmalectin has received an Patent issued in 2023 by the Patent issued in 2022
Slide 24: Bioxytran's Exit Strategy
Bioxytran’s Exit Strategy Licensing COVID-19 Antiviral Comparables $850 million & $350 million $425 million 22% royalties Partnership Divesting product line Copyright © Bioxytran 2025. All rights. 24
Slide 25: The Team
The Team MANAGEMENT David Platt PhD Ola Soderquist CPA, Mike Sheikh, Dr. Leslie Ajayi MD CEO, CSO, Chairman MSA, MBA, CCO CMO, Board Member Leader in Carbohydrate chemistry, CFO >10 years of business development >20 years of clinical development experience in founded five public companies, in life s
Slide 26: The Team - Board of Directors and Advisory Board
The Team BOARD OF DIRECTORS Advisory Board David Platt, PhD Chairman Director Chemical Engineer. Specialized in Complex Carbohydrate Chemistry. Avraham Mayevsky PhD, Professor Emeritus Created 5 public companies. Managed multiple clinical trials under FDA. Published two textbooks. Worldwide authorit
Slide 27: Symbol: BIXT (OTCQB)
Symbol: BIXT (OTCQB) SEC Fully Reporting Public Company (Audited) 2,100 Shareholders Location Formation Funding Boston, MA 2017 Accredited 89M Shares Outstanding Investors 65%+ Insider Ownership Licensing Strategy – Multiple Big Pharma Partners 37M Shares in Float All IP Developed In-House Focused o
Slide 28: Offering $2.4M
OFFERING INSIDERS 68 % OTHER RESTRICTED 100 % Offering Amount FLOAT 41 % $2.4M TOTAL OUTSTANDING 89 million One Share @$0.06 Plus One Warrant @$0.12 Warrant Expires in 5 years TOTAL FULLY DILUTED 319 million Copyright © Bioxytran 2025. All rights. 28
Slide 29: Use of Proceeds
Use of Proceeds Crossover Round – $2,400,000 ProLectin-M Estimated Project Cost in thousands USD $ 2,400 Development & GMP 1,040 Pre-Clinical 100 IND Submission 160 Clinical Trials 900 G&A 200 End Point Phase III Copyright © Bioxytran 2025. All rights. 29
Slide 30: Experienced Management Team, Value Inflection Point, Cost Efficient Development
Experienced Management Team Value Inflection Point Demonstrated ability to navigate regulatory Clinical Trial Milestone Successful. Phase II climate in record time & multiple jurisdictions double blind placebo control is completed and ready to be announce! Cost Efficient Development Funds spent on a
Slide 31: David Platt
75 2nd Ave., Suite 605 Needham MA, 02494 www.bioxytraninc.com David Platt info@bioxytraninc.com david.platt@bioxytraninc.com Copyright © Bioxytran 2025. All rights. 31